Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Fast Track Speeds Approval, Tufts Finds; Therapeutic Category Also Key

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

FDA’s fast track program may be the most successful of FDA’s user fee-era regulatory initiatives aimed at speeding new drug reviews, an analysis by the Tufts Center for the Study of Drug Development suggests.

You may also be interested in...

Oncology Review Division At The Head Of The Pack – But Can The Others Keep Up?

Analysis of drug review performance by division finds Cardiovascular & Renal Drugs Division to occupy the lower end of the spectrum. Staffing appears to be a vital component of review performance, giving weight to the researchers’ warning of impending wholesale staff turnover.

Big Pharma Keeps CNS Pipeline In-House; GI/Metabolism Left To Specialists

For the analysis, published in the September/October 2010 Tufts CSDD Impact Report, researchers tracked clinical activity at the 50 largest pharmaceutical and biopharmaceutical companies ranked by total 2006 worldwide sales. The study analyzed factors related to clinical approval success for compounds entering the clinic between 1993 and 2004.

Lessons Learned: New FDA Guidance On Meetings With Sponsors Adds Depth

FDA's new iteration of its guidance on meetings with sponsors reflects lessons learned during the surge in meeting requests the agency has had in the nine years since the original formal meetings final guidance was issued in February 2000

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts